Novartis Ag (NVSEF) FCF Margin (2009 - 2025)

Novartis Ag has disclosed FCF Margin across 14 years of filings, most recently posting 49.77% for Q2 2025.

• FCF Margin for Q2 2025 came in at 49.77%, up 873.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 20.87% (down 614.0% YoY), and the FY2025 annual result was 32.27%, down 3.0% from the prior year.
• FCF Margin came in at 49.77% for Q2 2025 at Novartis Ag, up from 31.63% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 2248.03% in Q4 2022 to a low of 26.5% in Q4 2021.
• The 5-year median for FCF Margin is 45.41% (2024), against an average of 215.39%.
• Across the five-year window, FCF Margin tumbled 287020 bps in 2021 and surged 222153 bps in 2022, its largest moves.
• Novartis Ag's FCF Margin stood at 26.5% in 2021, then surged by 8383 bps to 2248.03% in 2022, then sank by 99 bps to 31.21% in 2023, then grew by 1 bps to 31.63% in 2024, then soared by 57 bps to 49.77% in 2025.
• The last three FCF Margin figures came in at 49.77% (Q2 2025), 31.63% (Q4 2024), and 41.04% (Q2 2024), per Business Quant data.